Diagnostic and Prognostic Value of Soluble Syndecan-1 in Pleural Malignancies
Table 1
Demographic data.
Pleural effusions
Number of patients
Male (%)
Female (%)
Age, median (IQR)
Benign
93
63 (68)
30 (32)
68 (54–80)
Malignant
74
23 (31)
51 (69)
68 (62–78)
Lung cancer
43
14 (33)
29 (67)
70 (62–79)
Breast cancer
8
1 (12)
7 (88)
64 (47–80)
Ovarian and fallopian cancers
5
0 (0)
5 (100)
70 (66–78)
Other malignancies
8
3 (37)
5 (63)
65 (63–77)
Cancer of unknown primary
10
5 (50)
5 (50)
68 (52–80)
Malignant mesothelioma
89
79 (89)
10 (11)
70 (63–78)
Sera
Number of patients
Male (%)
Female (%)
Age, median (IQR)
Benign
66
52 (79)
14 (21)
59 (48–71)
Benign asbestos pleuritis
24
23 (96)
1 (4)
62 (54–73)
Malignant
74
44 (59)
30 (41)
61 (54–69)
Lung cancer
44
34 (77)
10 (23)
63 (57–70)
Breast cancer
9
1 (11)
8 (89)
56 (48–71)
Ovarian and fallopian cancers
3
0 (0)
3 (100)
57 (45–64)
Other malignancies
16
9 (56)
7 (44)
62 (52–72)
Cancer of unknown primary
2
1 (50)
1 (50)
56 (50–61)
Malignant mesothelioma
91
34 (37)
57 (63)
65 (56–69)
Epithelioid
62
23 (37)
39 (63)
65 (54–71)
Biphasic
13
4 (31)
9 (69)
57 (55–69)
Sarcomatoid
10
8 (80)
2 (20)
63 (61–65)
Undetermined
6
2 (33)
4 (66)
64 (55–70)
Age (IQR: interquartile range) and patient subgrouping in the two analysed materials. The high proportion of female mesothelioma patients in the serum material is most likely due to environmental asbestos and erionite exposure, which relates to geographical distribution and has also been reported by others [36].
